Descriptive results showed that after participation, 69 of 157 (44%) intervention-group clinicians used GLP-1 RAs with their patients with T2D compared with 51 of 157 (32.5%) comparison-group clinicians (Multimedia Appendix 2). Here, GLP1R is linked to type 2 diabetes mellitus.